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Purpose: To summarize the physiology and pathophysiology 
relevant to perioperative blood loss in children. Strategies to 
reduce blood losses are reviewed.
Methods: The literature was reviewed using the electronic 
library PUBMED and the Cochrane Database of Systematic 
Reviews. Relevant studies published in English or French with 
an English abstract are included. The following keywords were 
used: children, blood transfusion, surgical blood loss, erythro-
poietin, autologous blood, red blood cell saver, normovolemic 
hemodilution, desmopressin, aminocaproic acid, tranexamic 
acid, aprotinin, cardiac surgery, liver transplantation and sco-
liosis surgery.
Main findings: For patients with idiopathic scoliosis, predona-
tion with or without the addition of erythropoietin is a safe and 
effective way to avoid the use of allogenic blood products. For 
open heart procedures: whole blood of less than 48 hr is helpful 
for children of less than two years of age undergoing complex 
procedures; tranexamic acid may be helpful for cyanotic heart 
disease and, to a lesser degree, for reoperations; while anti-
kallikrein blood levels of aprotinin may both reduce the need 
for allogenic blood transfusions and improve postoperative 
oxygenation in infants. 
Conclusion: Reducing perioperative allogenic blood transfu-
sions is possible in pediatric patients provided that prophylactic 
measures are adapted to age, disease and type of surgery. 
Objectif : Revoir la littérature pertinente à la prise en charge des 
pertes sanguines péri-opératoires de l’enfant ainsi que les straté-
gies d’épargne sanguine.
Méthode : La littérature a été revue à l’aide de la banque de 
données électronique PUBMED et du Cochrane Database of 
Systematic Reviews. Les études pertinentes publiées en langue 
française ou anglaise avec résumé en langue anglaise ont été 
revues. Les mots-clés suivants ont été utilisés : enfant, transfusion 
sanguine, pertes sanguines chirurgicales, érythropoïétine, transfu-
sion autologue préprogrammée, récupérateur de globules rouges, 
hémodilution isovolémique, desmopressine, acide aminocaproïque, 
acide tranexamique, aprotinine, chirurgie cardiaque, transplanta-
tion hépatique et arthrodèse vertébrale.
Constatations principales : Pour les scolioses idiopathiques, 
la transfusion autologue programmée avec ou sans l’ajout 
d’érythropoïétine réduit l’administration de sang homologue. Pour 
les chirurgies à cœur ouvert, le sang complet de moins de 48 h est 
utile pour les corrections de cardiopathies complexes avant l’âge 
de deux ans, l’acide tranexamique est utile pour les corrections de 
cardiopathies cyanogènes et à un degré moindre pour les réinter-
ventions alors que l’aprotinine à dose anti-kallikréïne diminue les 
besoins transfusionnels et améliore l’oxygénation postopératoire en 
dessous de l’âge de un an. 
Conclusion : Il est possible de réduire les transfusions allogènes 
chez l’enfant si des mesures adaptées à l’âge, à la pathologie et au 
type de chirurgie sont appliquées. 
I
N normal children perioperative blood loss lead-
ing to administration of allogenic transfusion 
may be encountered if: the surgical site does 
not allow easy access to surgical hemostasis, the 
surgery is performed on highly vascularized tissues 
that are not easily sutured or cauterized (for example 
bone elements such as in spinal fusion or correc-
tion of craniosynostosis) or the surgery itself induces 
various disturbances of hemostasis (dilution of factors 
and induction of fibrinolysis as in cardiac surgery 
with the use of extracorporeal bypass). The pathol-
ogy justifying the surgical procedure may also induce 
various coagulation and/or hemostatic abnormalities. 
Children suffering from congenital cardiac or liver dis-
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ease may have thrombocytopenia, abnormal platelet 
function (congenital heart disease) and/or inadequate 
amounts of various coagulation factors.1 Perioperative 
management of children with congenital coagulation 
and hemostatic diseases will not be discussed in this 
review.
Developmental aspects of hemostasis
An excellent summary of the developmental physiolo-
gy of coagulation, based mainly on the extensive work 
of Maureen Andrew, may be found in a recent review 
by Kuhle et al. and is summarized in Table I.2 Since 
maternal coagulation factors do not cross the placental 
barrier, blood levels measured at birth are the result 
of fetal synthesis that starts around the fifth week of 
gestation. Fetal blood becomes clottable around 11 
weeks of gestation. Except fetal fibrinogen which has 
an increased content of sialic acid, all coagulation and 
inhibitor factors are qualitatively normal at birth, and 
differ from adults in their quantity only. Factor VIII 
would be the only factor present in normal quantity at 
birth. In neonates and up to six months of age where 
they reach approximately 80% of adult values, plasma 
levels of vitamin K-dependent factors (II, VII, IX 
and X) are reduced, but the prothrombin time (PT) 
remains within normal limits. The activated partial 
PT (aPTT) is slightly prolonged up to three months 
of age as a result of decreased blood levels of contact 
factors (XII, prekallikrein and high molecular-weight 
kininogens). A decrease in platelet function during 
the first years of life has also been shown.3 Clinical 
implications of the prolonged aPTT observed up to 
three months of age and of decreased platelet function 
throughout childhood are unclear, since measure-
ment of whole blood coagulation shows a relative 
hypercoagulable state as demonstrated by a decreased 
reaction-time with the thromboelastograph in infants 
(under one year of age).4 Moreover, the bleeding time 
is shorter in newborns. This might be due to higher 
levels of von Willebrand factor and increased hema-
tocrit. Finally, except for cardiac surgery with the use 
of extracorporeal bypass where higher blood losses 
in infants have been clearly demonstrated, neonates 
usually do not demonstrate excessive bleeding during 
surgery.5
In vitro studies report both increased and decreased 
heparin sensitivity for neonates. These apparently con-
tradictory results can be explained by an increase in 
the antithrombin to thrombin ratio (1.5:1 in neonates 
compared to an arbitrary reference value of 1:1 for 
adults). Thus, if the test used to measure anticoagula-
tion is based on the generation of thrombin, results 
will be compatible with increased heparin sensitivity.1,6 
Though an increased sensitivity of newborn and chil-
dren plasma to heparinoids has been described, chil-
dren under one year of age will require higher heparin 
doses per kilogram of body weight than adults.7,8
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TABLE I  Reference values for neonates, infants, children and adults: laboratory tests and thromboelastograph data
Laboratory test Neonates  Infants Children  Pre- and  Adults 
      adolescents
 1 day 30 days 6 months  1 to 5 yr 6 to 10 yr 10 to 16 yr 
Prothrombin  13.0 (10.1–15.9) 11.8 (10.0–14.3) 12.3 (10.7–13.9) 11.0 (10.6–11.4) 11.1 (10.1–12.1) 11.2 (10.2–12.0) 12.0 (11.0–14.0) 
time (sec)
International  1.0 (0.53–1.62) 0.79 (0.53–1.26) 0.88 (0.61–1.17) 1.00 (0.96–1.04) 1.01 (0.91–1.11) 1.02 (0.93–1.10) 1.10 (1.00–1.30) 
normalized ratio
Activated partial  42.9 (3.13–54.9) 40.4 (32.0–55.2) 35.5 (28.1–42.9) 30.0 (24.0–36.0) 31.0 (26.0–36.0) 32.0 (26.0–37.0) 33.0 (27.0–40.0) 
thromboplastin  
time (sec)
Thrombin clotting  23.5 (19.0–28.3) 24.3 (19.4–29.2) 25.5 (19.8–31.2)     
time (sec)
Bleeding time (min)    6.0 (2.50–10.0) 7.0 (2.50–13.0) 5.0 (3.00–8.00) 4.00 (1.00–7.00)
Thromboelastograph
Reaction time (min) 12.8 ± 3.7 13.0 ± 3.3 12.0 ± 4.0 13.5 ± 3.1 14.0 ± 3.4  16.1 ± 3.1
K (min) 8.3 ± 2.5 6.2 ± 1.5 6.6 ± 1.8 7.9 ± 1.7 8.5 ± 1.9  9.2 ± 2.4
α angle (°) 35.5 ± 10.1 45.8 ± 7.4 42.6 ± 8.9 36.9 ± 6.7 35.3 ± 7.6  30.1 ± 6.7
Maximal  58.6 ± 7.3 65.4 ± 5.2 61.3 ± 6.6 58.6 ± 4.9 58.3 ± 4.5  51.6 ± 5.8 
amplitude (mm)
Amplitude at  52.9 ± 7.8 58.8 ± 6.1 55.0 ± 6.6 52.1 ± 5.6 51.6 ± 5.3  46.6 ± 6.7 
60 min after  
maximal  
amplitude (mm)
Laboratory values are expressed as mean and range to encompass 95% of the population and thromboelastograph values as mean ± SD. 
From Kuhle et al. Sem Thromb Hemost 2003; 29: 329–37 and Miller et al. Anesth Analg 1997; 84: 745–8.
Preoperative laboratory investigation
The Canadian Anesthesiologists’ Society proposes that 
before any surgery: “Laboratory investigations indi-
cated by the history and physical examination should 
be carried out. These should take into consideration 
the physical condition of the patient and the proposed 
operation”. When the patient’s personal or familial 
history discloses possible congenital or acquired dis-
eases of hemostasis or the proposed surgery gener-
ally implies major blood loss, coagulation screening 
is indicated. Recommendations, however, are not as 
clear for healthy children undergoing a surgery with 
a low or moderate risk of intra- or postoperative 
bleeding. Though many valuable studies have tried to 
evaluate the cost/benefit ratio of routine coagulation 
screening tests before adeno-tonsillectomy, the ques-
tion remains unresolved. Although screening assays 
have been abandoned by many specialized centres, 
coagulation tests are still ordered by some physicians 
before an adeno or tonsillectomy (45–81%).9,10 Post-
tonsillectomy hemorrhage occurs in 1.6 to 3.5% of the 
patients and is less frequent in younger children (under 
three years of age) despite the risk of undiagnosed 
hematologic disease in those children.11,12 On the 
other hand, history alone may fail to detect patients 
with congenital or acquired bleeding disorders, even 
those with diseases as severe as hemophilia type A.13 In 
predicting adeno-tonsillectomy perioperative bleed-
ing, history coupled with routine classical laboratory 
screening tests (including PT, aPTT, platelets count) 
has both a low sensitivity and a very low post-test 
probability due to the low prevalence of bleeding. 
When routine coagulation tests are performed, abnor-
mal tests are found in approximately 3% of children 
but diseases susceptible to induce abnormal periopera-
tive bleeding occur in only 0.5% of the children, von 
Willebrand’s disease and factor XI deficiency being by 
far the two most common diseases encountered.14,15 
The prevalence of von Willebrand’s disease in the 
surgical population is estimated at 0.6%.16 Thus, if the 
clinician chooses to evaluate the coagulation status of 
all children undergoing adeno-tonsillectomy, aPTT 
measurement and a platelet function test would prob-
ably be the most useful. For evaluation of platelet 
function, bleeding time was often performed in this 
setting. However this test (which can leave long term 
scars) can be advantageously replaced by newer on-site 
monitoring devices such as the PFA-100 which has 
been shown to offer a higher sensitivity to detect von 
Willebrand’s disease: for example, in one study, 100 
and 87% for epinephrine and adenosine diphosphate 
cartridge, respectively, compared to only 37% for the 
bleeding time.17 For PT or international normalized 
ratio measurements in the pediatric population, and 
for international normalized ratio values ranging 
from 1.05 to 5.25, the near patient instrument with 
the least bias relative to the classical laboratory test 
(CA-1000) is the RapidpointCoag® (r2 = 0.923), the 
correlations (r2) of the CoaguCheck®, Hemochron 
Jr®., and ProTime® being 0.877, 0.834, and 0.885, 
respectively.18 Bilirubin levels up to 20 mg·dL–1 (342 
µmol·L–1) do not interfere with any of these methods. 
For other types of surgery, preoperative coagulation 
tests have been reported to be useful in predicting the 
magnitude of blood losses in open heart, liver trans-
plant and scoliosis surgery.19–21 Routine coagulation 
tests have also been recommended by some before any 
neuraxial blockade in children under one year of age, 
but the real benefit of this recommendation remain to 
be shown.22 
Patient and surgical risk factors known to 
increase perioperative blood loss
A good knowledge of the surgical technique itself will 
help in predicting blood loss, determine the extent of 
prophylactic measures needed to avoid allogenic blood 
transfusions, and prepare for blood loss replacement. 
For scoliosis surgery, the number of fused vertebrae 
and the presence or absence of an underlying disease 
such as neuromuscular dystrophies are probably the 
most important factors that determine the magnitude 
of blood loss.23,24 For repair of craniosynostosis, the 
type of skull deformation and surgical procedure 
determine the extent of intraoperative bleeding.25 For 
orthognatic surgery, double-jaw procedures result 
in more blood loss than single-jaw procedures, boys 
have a higher average blood loss than girls, but aver-
age blood loss is not significantly affected by patients’ 
age.26 For pediatric open heart surgery, risk factors 
clearly associated with increased blood loss include: 
age less than one month, body weight under 8 kg, 
complexity of the procedure (arterial switches for 
transposition of the great vessels, Fontan procedures, 
Glenn shunts and truncus arteriosus repairs), duration 
of cardiopulmonary bypass, resternotomy, and low 
platelet count during cardiopulmonary bypass.1,5,27–30 
For pediatric liver transplants, apart from retransplan-
tation, factors that have been associated with increased 
intraoperative blood losses include: hypoplastic portal 
vein, use of a reduced-size liver graft, requirement of 
in-hospital supportive care, intra-abdominal malforma-
tions and signs of severe liver failure (encephalopathy, 
ascites, prolonged PT).20,31–33 Children younger than 
two years, and particularly those under one year of age 
experience higher blood loss.34,35 Transplantation of a 
reduced (fraction of an adult human organ) liver not 
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only increases intra- and postoperative blood loss, but 
has been associated with an increase in the percent-
age of patients undergoing reoperation for continued 
blood loss, from 9.6 to 19.2%.36
Reducing allogenic blood transfusions
As in adults, various strategies have been used to 
reduce allogenic blood transfusion in children.37–51 
Of all the types of surgeries, spinal fusion and cardiac 
operations have been the most extensively studied 
(Tables II and III). For patients with idiopathic sco-
liosis, predonation with or without the addition of 
erythropoietin is probably the safest and the most 
effective way to avoid the use of allogenic blood 
products. When an adequate amount of predonated 
blood is available, acute normovolemic hemodilu-
tion, intraoperative blood salvage and retransfusion, 
as well as antifibrinolytics agents offer little to further 
reduce allogenic blood transfusion, with the possible 
exception of patients with predicted blood losses over 
2000 mL or small body weight.52 Desmopressin has 
been proven ineffective for idiopathic as well as neu-
romuscular disease induced-scoliosis.43,44 The safety 
of retransfusing shed wound blood has not been well 
established. This practice carries a definite risk of bac-
terial contamination and, for scoliosis or open heart 
surgery,53 cannot be recommended. Recombinant 
factor VIIa may be another therapeutic tool to reduce 
perioperative allogenic blood transfusion, but has not 
been studied systematically in children so far. This 
drug has, however, been reported to benefit two 
patients with neuromuscular disease induced-scolio-
sis with severe postoperative dilutional coagulopathy 
unresponsive to plasma administration.54
Blood conservation strategies studied for open heart 
surgery are summarized in Table III.28,29,55–63 The 
population studied should be taken into account to 
interpret published results: age, complexity of surgery, 
cyanotic/acyanotic disease and reoperations.1,61 When 
available, whole blood of less than 48 hr is helpful 
TABLE II  Reducing allogenic blood transfusions in children undergoing non-cardiac surgery
 Craniostenosis repair Spinal fusion Liver transplantation Study protocol Authors
Erythropoietin ↓ABT   Prospective randomized Fearon et al.37
  ↓ABT  Retrospective, more  Vitale et al.38 
    effective in idiopathic  
    scoliosis
Red blood cell  ↓ABT  Retrospective, more  Murray et al.39 
predonation    effective in idiopathic  
    scoliosis
Acute  →ABT   Prospective randomized Hans et al.40 
intraoperative 
normovolemic  
hemodilution  ↓aBT; →ABT  Retrospective, case control Copley et al.41
Intraoperative   ↓aBT; →ABT   Retrospective,  Siller et al.42 
autotransfusion    idiopathic scoliosis
Desmopressin  →ABT or aBT  Prospective, randomized, Guay et al.43 
    idiopathic scoliosis
  →ABT  Prospective, randomized,  Theroux et al.44 
    neuromuscular disease
  →BL  Prospective, randomized,  Letts et al.45 
    neuromuscular disease
Aminocaproic acid  ↓aBT  Prospective, non- Florentino-Pineda et al.46 
    randomized, idiopathic  
    scoliosis
Tranexamic acid  ↓BL for secondary  Prospective, randomized,  Neilipovitz et al.,47 
  scoliosis, →aBT* mixed population Sethna48
Aprotinin  ↓BL and number  Prospective, mixed  Cole49 
  of transfused unit population 
  →BL  Prospective, randomized  Khoshhal et al.50 
    idiopathic scoliosis
   →ABT Retrospective  Rentoul et al.51
ABT = allogenic blood transfusion; aBT = autologous blood transfusion; BL = blood loss. ↓ = decrease or → = no change in the percent-
age of patients with ABT or aBT; or BL. *For reference 48, the volume of transfused blood was decreased, but not the number of patients 
transfused.
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for children less than two years of age undergoing 
complex procedures.28 The efficacy of fresh whole 
blood might be attributed to better platelet preserva-
tion. Platelet predonation and reinfusion is an elegant 
technique to decrease bypass induced-platelet activa-
tion.62,64 Erythropoietin with red blood cell predona-
tion could be helpful in acyanotic heart disease.55 The 
addition of fresh frozen plasma to the pump prime 
could possibly help children with cyanotic heart disease 
and those with complex surgery, but the risk of trans-
mitting infectious diseases must be weighed against the 
potential benefits. Among the antifibrinolytic agents, 
tranexamic acid might be the most appropriate, at 
least for cyanotic heart disease and, to a lesser degree, 
for reoperations. Apart from its lower cost, since it is 
entirely synthetic, risks of disease transmission should 
be inexistent. Moreover, risks of inducing an anaphylac-
tic reaction after reexposure are much lower than those 
reported for aprotinin. One study, however, suggests 
that, in infants (less than 10 kg of body weight), if anti-
kallikrein blood levels are maintained throughout the 
surgery, aprotinin might not only reduce the need for 
allogenic blood transfusions, but might also improve 
postoperative oxygenation.65 
Administration of blood products
Blood volume can be estimated from the patient’s body 
weight and age (Table IV). Maximal blood losses allowed 
before administration of red blood cells and plasma will 
vary according to age and associated diseases. There 
are actually very few pediatric data which could help 
determine the minimal acceptable hemoglobin con-
centration in children. In one study of more than 200 
pediatric cardiopulmonary arrests, there was no long 
term survival in children with a pre-arrest hemoglobin 
concentration less than 57 g·L–1.66 Some authors believe 
that infants less than four months old should be consid-
ered as a different population, while others have fixed a 
limit at one year of age.67,68 For children over six to 12 
months of age without cardiac or respiratory disease, 
a minimal hemoglobin concentration of 70 g·L–1, as 
recommended for adults, is probably acceptable.69 For 
younger patients, it is probably advisable to maintain a 
minimal hemoglobin concentration of 80 to 90 g·L–1,68 
although clinical data to support such a recommenda-
tion are lacking.  Assuming that blood volume remains 
normal, the maximal amount of blood loss that can be 
tolerated before administration of red blood cells can be 
calculated with the following formula:
TABLE III  Reducing allogenic blood transfusion in pediatric open heart surgery
 Acyanotic Cyanotic Mixed population Complex surgery Reoperation Study protocol Authors
Erythropoietin   ↓ABT*   Compared to  Sonzogni et al.55 
      historical controls
Desmopressin   →BL   Prospective  Seear et al.29 
      randomized
    →BL  Prospective  Reynolds et al.56 
      randomized
Aminocaproic acid →BL ↓BL    Prospective  McClure et al.57 
      randomized
Tranexamic acid  ↓BL, ABT     Prospective  Zonis et al.58 
  in mL·kg–1    randomized
    ↓BL and   Prospective  Reid et al.59 
    number of donor   randomized 
    unit exposure
Aprotinin     ↓BL and  Prospective  D’Errico et al.60 
     number of  randomized 
     donor unit  
     exposure
Autologous  ↓BL     Prospective  Hiramatsu et al.62 
platelet       non-randomized 
concentrates
Fresh frozen   ↓BL ↑Number of  ↓BL  Prospective  Oliver et al.63 
plasma in the prime  unit transfused   randomized with  
      post hoc analysis
Whole blood of less than 48 hr   ↓BL†  Prospective  Manno et al.28 
      non-randomized
ABT = allogenic blood transfusion; BL = blood loss; ↓ = decrease or → = no change in the percentage of patients with ABT or in BL. * 
Plus two predonated units of 6 mL·kg–1. †Less than two years of age.
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MBL (mL) = [(Hcti – Hctf)/Hctm] × EBV
Where:
MBL: maximal blood loss allowed before administra-
tion of red blood cells
Hcti: initial hematocrit level 
Hctf: minimal hematocrit level that will be tolerated 
according to age and underlying diseases
Hctm: mean hematocrit level defined as 
(Hctf+Hcti)/2
EBV: estimated blood volume (Table IV)
Irradiated blood is recommended for intrauter-
ine red blood cell transfusions to the fetus, select-
ed immunocompromised infants, newborns infants 
receiving blood from a relative, and infants who have 
previously received an in utero transfusion.70 Most 
guidelines also recommend the provision of cyto-
megalovirus-negative blood components for low birth 
weight infants.70
For children over six months of age, criteria for 
administration of fresh frozen plasma and platelet con-
centrates are the same as for adult patients. When the 
extent of blood loss approaches one blood volume, 
PT, aPTT and platelet count should be determined. 
With active bleeding and a PT and/or aPTT longer 
than one and a half times normal values, 15 to 20 
mL·kg–1 of fresh frozen plasma may be administered. 
For infants less than six months of age, many clinicians 
will start the administration of fresh frozen plasma 
with blood losses between 20 to 50% of the estimated 
blood volume as blood levels of coagulation factors 
are lower in this age group, and the administration 
of crystalloids as the sole replacement therapy for 
blood loss often leads to hemodynamic instability. 
Administration of fresh frozen plasma may also be 
indicated earlier for children with certain underly-
ing diseases, such as hepatic insufficiency (when 
presenting for liver transplantation) or congenital 
cardiopathy.71,72 Though the literature on this subject 
is virtually non existent, administration of colloid 
solutions in children is part of the standard practice of 
many centers. At least one study demonstrated that, in 
children, hemostatic variables will not be affected by 
the administration of colloid solutions (even after car-
diopulmonary bypass) until a volume greater than 20 
mL·kg–1 is administered.73 The administration of 0.1 
unit of platelets per kilogram of body weight should 
increase the platelet count by 7 to 11 G·L–1. The 
minimal acceptable platelet count will vary between 
50 and 100 G·L–1 depending on the type of surgery 
and the presence of other hemostatic diseases and/
or coagulopathies. Administration of 0.5 U·kg–1 of 
cryoprecipitate (when available) may be indicated for 
factor VIII levels lower than 0.5 U·mL–1 or fibrinogen 
levels lower than 1 g·L–1 and to restore blood factor 
levels in infants for whom the administration of large 
amounts of fluids may pose a problem. For example, 
in infants less than 8 kg of body weight who have 
undergone open heart surgery, coagulation factor lev-
els are better restored by cryoprecipitates than by fresh 
frozen plasma, which may induce further dilution of 
coagulation factors.27 If cryoprecipitates are unavail-
able, specific factor concentrates may be used.
Warming of blood products is mandatory in chil-
dren who may be particularly sensitive to hypother-
mia. Citrate intoxication with hypocalcemia is possible 
if the speed of administration exceeds 3 mL·kg–1·min–1 
for red blood cells and 1.5 to 2.0 mL·kg–1·min–1 for 
fresh frozen plasma. Hyperkalemia has also been 
reported with rapid red blood cell administration in 
children, especially if volemia has not been properly 
restored first.74
Conclusion
The management of perioperative blood loss in 
children requires good clinical knowledge of the 
developmental physiology and of the pathophysiol-
ogy of diseases affecting children coming to surgery. 
Reducing allogenic blood transfusions is possible in 
this age group, provided that prophylactic measures 
are adapted to age, disease and type of surgery. 
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